ATE333285T1 - Attenuierte salmonella mutanten, welche das vi- antigen konstant exprimieren - Google Patents

Attenuierte salmonella mutanten, welche das vi- antigen konstant exprimieren

Info

Publication number
ATE333285T1
ATE333285T1 AT99919755T AT99919755T ATE333285T1 AT E333285 T1 ATE333285 T1 AT E333285T1 AT 99919755 T AT99919755 T AT 99919755T AT 99919755 T AT99919755 T AT 99919755T AT E333285 T1 ATE333285 T1 AT E333285T1
Authority
AT
Austria
Prior art keywords
antigen
salmonella mutants
same
constantly express
attenuate
Prior art date
Application number
AT99919755T
Other languages
English (en)
Inventor
Fernando R Noriega
Marcelo Sztein
Myron M Levine
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE333285T1 publication Critical patent/ATE333285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99919755T 1998-05-13 1999-04-30 Attenuierte salmonella mutanten, welche das vi- antigen konstant exprimieren ATE333285T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/076,761 US6190669B1 (en) 1998-05-13 1998-05-13 Attenuated mutants of salmonella which constitutively express the Vi antigen

Publications (1)

Publication Number Publication Date
ATE333285T1 true ATE333285T1 (de) 2006-08-15

Family

ID=22134022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99919755T ATE333285T1 (de) 1998-05-13 1999-04-30 Attenuierte salmonella mutanten, welche das vi- antigen konstant exprimieren

Country Status (16)

Country Link
US (1) US6190669B1 (de)
EP (1) EP1076566B1 (de)
JP (1) JP4363782B2 (de)
AT (1) ATE333285T1 (de)
AU (1) AU754795B2 (de)
CA (1) CA2328056C (de)
DE (1) DE69932425T2 (de)
DK (1) DK1076566T3 (de)
ES (1) ES2268864T3 (de)
HU (1) HUP0101747A3 (de)
MX (1) MXPA00011075A (de)
NO (1) NO20005672L (de)
NZ (1) NZ508110A (de)
PL (1) PL192378B1 (de)
WO (1) WO1999058146A1 (de)
ZA (1) ZA200006381B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
MXPA00012796A (es) * 1999-12-28 2002-05-23 Akzo Nobel Nv Vacuna de salmonella.
PL359293A1 (en) * 2000-04-20 2004-08-23 University Of Maryland, Baltimore Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
WO2004001020A2 (en) * 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and means to promote gut absorption
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
EP1941024B1 (de) * 2005-10-28 2013-07-31 University of Maryland, Baltimore Gedämpfte enterische salmonellen-paratyphi a und verwendungen davon
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062371A2 (en) * 2005-11-23 2007-05-31 University Of Maryland, Baltimore Live vector vaccine and uses thereof
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
BRPI0621490A2 (pt) * 2006-03-20 2011-12-13 Univ Bruxelles cepa mutante atenuada de uma bactéria infectante de espécies veterinárias, vacina para imunização de espécies veterinárias contra uma infecção bacteriana, método para imunizar uma espécie veterinária contra uma infecção bacteriana, uso de uma cepa mutante atenuada e método para distinção sorológica entre animais vacinados e animais infectados por uma cepa alelo-selvagem
EP2004802A1 (de) * 2006-03-20 2008-12-24 Vrije Universiteit Brussel Abgeschwächter salmonella-lebendimpfstoff
EP2857038B1 (de) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen
EP3351268B1 (de) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Behandlung von immunerkrankungen durch mukosale abgabe von antigenen
US20110020399A1 (en) * 2007-04-16 2011-01-27 University Of Maryland, Baltimore Vaccines and Immunomodulatory Therapies for Tularemia
US9125854B2 (en) * 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
NO2525817T3 (de) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
WO2013126622A1 (en) * 2012-02-24 2013-08-29 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
EP2956165B1 (de) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Zusammensetzungen und verfahren zur verstärkung von immunreaktionen gegenüber eimeria oder zur begrenzung von eimeria-infektionen
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
KR20240054373A (ko) * 2021-09-10 2024-04-25 리젠츠 오브 더 유니버시티 오브 미네소타 종양의 비독성 콜로니화를 위해 조작된 살모넬라

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5783196A (en) 1996-04-09 1998-07-21 University Of Maryland At Baltimore Gua mutants of shigella spp. and vaccines containing the same

Also Published As

Publication number Publication date
AU3740599A (en) 1999-11-29
EP1076566A4 (de) 2005-01-05
PL344593A1 (en) 2001-11-05
HUP0101747A2 (hu) 2001-09-28
ZA200006381B (en) 2002-02-07
PL192378B1 (pl) 2006-10-31
NO20005672L (no) 2001-01-15
NZ508110A (en) 2002-10-25
AU754795B2 (en) 2002-11-28
CA2328056A1 (en) 1999-11-18
WO1999058146A1 (en) 1999-11-18
EP1076566A1 (de) 2001-02-21
ES2268864T3 (es) 2007-03-16
MXPA00011075A (es) 2002-04-24
NO20005672D0 (no) 2000-11-10
DE69932425T2 (de) 2007-03-08
HUP0101747A3 (en) 2002-03-28
JP4363782B2 (ja) 2009-11-11
EP1076566B1 (de) 2006-07-19
US6190669B1 (en) 2001-02-20
DK1076566T3 (da) 2006-11-13
DE69932425D1 (de) 2006-08-31
JP2002514398A (ja) 2002-05-21
CA2328056C (en) 2010-07-06

Similar Documents

Publication Publication Date Title
DE69932425D1 (de) Attenuierte salmonella mutanten, welche das vi-antigen konstant exprimieren
ATE454163T1 (de) Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren
FI912595A0 (fi) Stoetdaempare, speciellt foer motorfordon.
DK142391D0 (da) Indretning til tilberedning, servering og opbevaring af f.eks. madvarer
FI916020A7 (fi) Kommunikationsanordning, speciellt terminalanordning foer telefontrafik.
FI912834A0 (fi) Polyvinylalkoholharts, som aer loesligt i vattenhaltiga pappersbestrykningskompositioner med hoeg torrsubstanshalt utan yttre uppvaermning.
FI906340A7 (fi) Flerkanalanordning foer maetning av svaga, lokal- och tidsberoende magnetfaelt.
FI904004L (fi) Anordning foer genomfoerande av avpumpning i synnerhet fraon kanaler, brunnar, tankar eller motsvarande.
FI916019L (fi) Kommunikationsanordning, speciellt terminalanordning foer telefontrafik.
IT8120393A0 (it) Mutanti batterici, procedimento per produrli e vaccini vivi che licontengono.
FI914994A7 (fi) Elmotordrivet doerrlaos, speciellt roerram-doerrlaos.
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
FR2663112B1 (fr) Appareil de refrigeration, en particulier refrigerateur-armoire menager.
DE69105285D1 (de) Gegen Wärme vakuumisolierter Behälter.
ITGE930084A0 (it) Sicura,in particolare per fucili subaquei o simili.
DE3873278D1 (de) Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
FI910018A7 (fi) Kolv, speciellt kopplingskolv foer fyrtaktsfoerbraenningsmotorer.
FR2665247B1 (fr) Appareil frigorifique, notamment refrigerateur-armoire ou congelateur-armoire.
FI911258A0 (fi) Foer kylmaskin, i synnerhet foer hushaollskylskaop avsedd plaotkondensator.
TR199600082A2 (tr) Gelistirilmis üstüne yazma özelliklerine sahip, ozona zarar vermeyen düzeltme yapma sivisi.
FI912566L (fi) Kombinationsmaterial, vilket innehaoller haordaemnespartiklar.
TR199600893A2 (tr) Sürme cekmeceli dikine firin.
FI912699A0 (fi) Expenderingskropp, saerskilt foer massautloppslaodan i en pappersmaskin.
IT9047812A0 (it) Complesso per la stabilizzazione del rachide dorso-lombo-sacrale e relativo metodo di stabilizzazione.
IT8223644A0 (it) Serracavo, particolarmente per elettrodomestici o simili.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1076566

Country of ref document: EP

REN Ceased due to non-payment of the annual fee